DelveInsight’s, “Advanced Merkel Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including Advanced Merkel Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Latest Developmental Activities in the Advanced Merkel Cell Carcinoma Treatment Landscape
Discover the recent breakthroughs happening in the Advanced Merkel Cell Carcinoma Pipeline landscape @ Advanced Merkel Cell Carcinoma Pipeline Outlook
Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report
Advanced Merkel Cell Carcinoma Emerging Drugs Profile
Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.
In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan.
Advanced Merkel Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Advanced Merkel cell carcinoma. The companies which have their Advanced Merkel cell carcinoma drug candidates in the most advanced stage, i.e. phase II include, Exelixis.
Get More Information on the Advanced Merkel cell carcinoma Drugs and Companies of Report @ Advanced Merkel cell carcinoma Ongoing Clinical Trials Analysis
Scope of the Advanced Merkel cell carcinoma Pipeline Report
Find out more about the list of FDA-approved drugs for Advanced Merkel Cell Carcinoma @ Advanced Merkel Cell Carcinoma Treatment Landscape
Table of Content
Got Queries? Find out the related information on Advanced Merkel Cell Carcinoma Preclinical and Discovery Stage Products @ Advanced Merkel Cell Carcinoma Drugs, Unmet Needs and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/